Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily pill regrow hair in alopecia areata? a trial seeks answers

NCT ID NCT07733765

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Sep 11, 2026 · Updated 5 times

Summary

This phase 3 trial tests whether the experimental drug ritlecitinib can safely and effectively regrow hair in people aged 12 and older with moderate alopecia areata, a condition causing patchy hair loss. Participants take a daily capsule for 24 weeks, with some receiving placebo. The study compares hair regrowth between groups to see if ritlecitinib offers a real benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental drug called ritlecitinib
What this could lead to
If it works, ritlecitinib could offer a new treatment option for people with moderate alopecia areata, potentially regrowing significant hair.
What could go wrong
This is a phase 3 trial, but results are not yet known. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 336 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria * 18 years or older (or the minimum age of consent in accordance with local regulations) at screening. Adolescents (12 to \<18 years of age at screening) are also eligible for this study, but only if permitted by the local IRB/EC and local regulatory health authority (if applicable). Where these approvals have not been granted, only participants 18 years of age and older at screening will be enrolled * Have a clinical diagnosis of AA with no other etiology of hair loss. * Have \>20% to \<50% hair loss of the scalp, as measured by SALT. * Current AA episode of hair loss ≥6 months and ≤10 years (Current episode is defined as the continuous period of AA-related scalp hair loss since the last time the subject had no visible scalp patches). Key Exclusion Criteria 1\. Diseases or conditions affecting hair loss, including: * Other types of alopecia (including, but not limited to, traction and scarring alopecia, telogen effluvium). Participants with androgenetic alopecia will be excluded. * Other scalp disease that may impact AA assessment (eg, scalp psoriasis, dermatitis, etc.). * Active systemic diseases that may cause hair loss (eg, lupus erythematosus, thyroiditis, systemic sclerosis, lichen planus, etc).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bexley Dermatology Research

    NOT_YET_RECRUITING

    Bexley, Ohio, 43209, United States

  • California Dermatology & Clinical Research Institute

    NOT_YET_RECRUITING

    Encinitas, California, 92024, United States

  • Center for Clinical Studies, LTD. LLP

    NOT_YET_RECRUITING

    Houston, Texas, 77004, United States

  • Centre de Recherche Saint-Louis (Québec)

    NOT_YET_RECRUITING

    Québec, Quebec, G1W 4R4, Canada

  • Clinical and Translational Research Center (CTRC)

    NOT_YET_RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • Cutaneous Translational Research Program (CTReP)

    NOT_YET_RECRUITING

    Baltimore, Maryland, 21287, United States

  • Dawes Fretzin Clinical Research Group, LLC

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Dermatology Associates of Plymouth Meeting

    RECRUITING

    Plymouth Meeting, Pennsylvania, 19462, United States

  • Dermatology Specialists of Spokane

    NOT_YET_RECRUITING

    Spokane, Washington, 99202, United States

  • Endeavor Health

    NOT_YET_RECRUITING

    Skokie, Illinois, 60077, United States

  • Hospital of the University of Occupational and Environmental Health, Japan

    NOT_YET_RECRUITING

    Kitakyushu-shi, Fukuoka, 807-8556, Japan

  • Johns Hopkins Hospital Investigational Drug Services (IDS) Pharmacy

    NOT_YET_RECRUITING

    Baltimore, Maryland, 21287, United States

  • NW Dermatology Institute

    NOT_YET_RECRUITING

    Portland, Oregon, 97210, United States

  • Niigata University Medical & Dental Hospital

    RECRUITING

    Niigata, 951-8520, Japan

  • Principle Research Solutions

    NOT_YET_RECRUITING

    Spokane, Washington, 99202, United States

  • Revival Research Institute, LLC

    RECRUITING

    Troy, Michigan, 48084, United States

  • Skin Research of South Florida

    RECRUITING

    Miami, Florida, 33173, United States

  • Texas Dermatology and Laser Specialists

    RECRUITING

    San Antonio, Texas, 78218, United States

  • UNC Dermatology and Skin Cancer Center

    NOT_YET_RECRUITING

    Chapel Hill, North Carolina, 27516, United States

  • University of Iowa

    NOT_YET_RECRUITING

    Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.